...
首页> 外文期刊>Functional & integrative genomics >Increased accumulation of the cardio-cerebrovascular disease treatment drug tanshinone in Salvia miltiorrhiza hairy roots by the enzymes 3-hydroxy-3-methylglutaryl CoA reductase and 1-deoxy-D-xylulose 5-phosphate reductoisomerase
【24h】

Increased accumulation of the cardio-cerebrovascular disease treatment drug tanshinone in Salvia miltiorrhiza hairy roots by the enzymes 3-hydroxy-3-methylglutaryl CoA reductase and 1-deoxy-D-xylulose 5-phosphate reductoisomerase

机译:3-羟-3-甲基戊二酰辅酶A还原酶和1-脱氧-D-木酮糖5-磷酸还原异构酶增加丹参在毛丹根中的心脑血管疾病药物的积累

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Tanshinone is widely used for treatment of cardio-cerebrovascular diseases with increasing demand. Herein, key enzyme genes SmHMGR (3-hydroxy-3-methylglutaryl CoA reductase) and SmDXR (1-deoxy-Dxylulose 5-phosphate reductoisomerase) involved in the tanshinone biosynthetic pathway were introduced into Salvia miltiorrhiza (Sm) hairy roots to enhance tanshinone production. Over-expression of SmHMGR or SmDXR in hairy root lines can significantly enhance the yield of tanshinone. Transgenic hairy root lines coexpressing HMGR and DXR (HD lines) produced evidently higher levels of total tanshinone (TT) compared with the control and single gene transformed lines. The highest tanshinone production was observed in HD42 with the concentration of 3.25 mg g~(?1) DW. Furthermore, the transgenic hairy roots showed higher antioxidant activity than control. In addition, transgenic hairy root harboring HMGR and DXR (HD42) exhibited higher tanshinone content after elicitation by yeast extract and/or Ag~+ than before. Tanshinone can be significantly enhanced to 5.858, 6.716, and 4.426 mg g~(?1) DW by YE, Ag~+, and YE-Ag~+ treatment compared with noninduced HD42, respect i vely. The content of cryptotanshinone and dihydrotanshinone was effectively elevated upon elicitor treatments, whereas there was no obvious promotion effect for the other two compounds tanshinone I and tanshinone IIA. Our results provide a useful strategy to improve tanshinone content as well as other natural active products by combination of genetic engineering with elicitors.
机译:丹参酮被广泛用于治疗心脑血管疾病,其需求日益增加。在这里,丹参酮生物合成途径中涉及的关键酶基因SmHMGR(3-羟基-3-甲基戊二酰辅酶A还原酶)和SmDXR(1-脱氧-二甲苯基葡萄糖5-磷酸还原异构酶)被引入丹参多毛根中以增强丹参酮的产生。 。 SmHMGR或SmDXR在毛状根系中的过表达可以显着提高丹参酮的产量。与对照和单基因转化品系相比,共表达HMGR和DXR的转基因有毛根系(HD品系)产生的总丹参酮(TT)水平明显更高。在HD42中,丹参酮的产量最高,浓度为3.25 mg g〜(?1)DW。此外,转基因的毛状根显示出比对照更高的抗氧化活性。此外,带有HMGR和DXR(HD42)的转基因毛状根在酵母提取物和/或Ag〜+诱导后显示出更高的丹参酮含量。与未经诱导的HD42相比,通过YE,Ag〜+和YE-Ag〜+处理,丹参酮可显着提高至5.858、6.716和4.426 mg g〜(?1)DW。引发剂处理后,隐丹参酮和二氢丹参酮的含量有效提高,而其他两种化合物丹参酮I和丹参酮IIA则没有明显的促进作用。我们的结果为通过结合基因工程与激发子提高丹参酮以及其他天然活性产物的含量提供了有用的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号